Single Dose of Phosphatidylinositol 3-Kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study

Overview

Journal Diabetes

Specialty Endocrinology

Date 2024 Sep 12

PMID 39264822

Authors

Joshua R Cook

Nur Bedeir

Zachary D Sone

Julia Wattacheril

Henry N Ginsberg

Blandine Laferrere

Affiliations

Soon will be listed here.

Abstract

Article Highlights:

References

Petersen M, Shulman G . Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98(4):2133-2223. PMC: 6170977. DOI: 10.1152/physrev.00063.2017. View

Kaneko K, Ueki K, Takahashi N, Hashimoto S, Okamoto M, Awazawa M . Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms. Cell Metab. 2010; 12(6):619-32. PMC: 3736578. DOI: 10.1016/j.cmet.2010.11.005. View

Smith G, Shankaran M, Yoshino M, Schweitzer G, Chondronikola M, Beals J . Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2019; 130(3):1453-1460. PMC: 7269561. DOI: 10.1172/JCI134165. View

Rugo H, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P . Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021; 22(4):489-498. DOI: 10.1016/S1470-2045(21)00034-6. View

Ahmad T, Haeusler R . Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs. Nat Rev Endocrinol. 2019; 15(12):701-712. PMC: 6918475. DOI: 10.1038/s41574-019-0266-7. View

Huang-Doran I, Tomlinson P, Payne F, Gast A, Sleigh A, Bottomley W . Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations. JCI Insight. 2016; 1(17):e88766. PMC: 5070960. DOI: 10.1172/jci.insight.88766. View

Gajewska M, Blumenstein L, Kourentas A, Mueller-Zsigmondy M, Lorenzo S, Sinn A . Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection. AAPS J. 2020; 22(6):134. DOI: 10.1208/s12248-020-00511-7. View

Liang H, Lum H, Alvarez A, Garduno-Garcia J, Daniel B, Musi N . A low dose lipid infusion is sufficient to induce insulin resistance and a pro-inflammatory response in human subjects. PLoS One. 2018; 13(4):e0195810. PMC: 5897027. DOI: 10.1371/journal.pone.0195810. View

Juric D, Rodon J, Tabernero J, Janku F, Burris H, Schellens J . Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018; 36(13):1291-1299. PMC: 5920739. DOI: 10.1200/JCO.2017.72.7107. View

10.

Smith G, Magkos F, Reeds D, Okunade A, Patterson B, Mittendorfer B . One day of mixed meal overfeeding reduces hepatic insulin sensitivity and increases VLDL particle but not VLDL-triglyceride secretion in overweight and obese men. J Clin Endocrinol Metab. 2013; 98(8):3454-62. PMC: 3733854. DOI: 10.1210/jc.2013-1786. View

11.

Wajngot A, Giacca A, Grill V, Vranic M, Efendic S . The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A. 1992; 89(13):6035-9. PMC: 402133. DOI: 10.1073/pnas.89.13.6035. View

12.

Bendavid I, Lobo D, Barazzoni R, Cederholm T, Coeffier M, de van der Schueren M . The centenary of the Harris-Benedict equations: How to assess energy requirements best? Recommendations from the ESPEN expert group. Clin Nutr. 2020; 40(3):690-701. DOI: 10.1016/j.clnu.2020.11.012. View

13.

Kitamura T, Kahn C, Accili D . Insulin receptor knockout mice. Annu Rev Physiol. 2002; 65:313-32. DOI: 10.1146/annurev.physiol.65.092101.142540. View

14.

Chavakis T, Alexaki V, Ferrante Jr A . Macrophage function in adipose tissue homeostasis and metabolic inflammation. Nat Immunol. 2023; 24(5):757-766. DOI: 10.1038/s41590-023-01479-0. View

15.

Andre F, Ciruelos E, Juric D, Loibl S, Campone M, Mayer I . Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2020; 32(2):208-217. DOI: 10.1016/j.annonc.2020.11.011. View

16.

Semple R, Sleigh A, Murgatroyd P, Adams C, Bluck L, Jackson S . Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009; 119(2):315-22. PMC: 2631303. DOI: 10.1172/JCI37432. View

17.

Bertho M, Patsouris A, Augereau P, Robert M, Frenel J, Blonz C . A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Expert Opin Drug Metab Toxicol. 2020; 17(2):139-152. DOI: 10.1080/17425255.2021.1844662. View

18.

Tankova T, Senkus E, Beloyartseva M, Borstnar S, Catrinoiu D, Frolova M . Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers (Basel). 2022; 14(7). PMC: 8997133. DOI: 10.3390/cancers14071598. View

19.

Cook J, Hawkins M, Pajvani U . Liver insulinization as a driver of triglyceride dysmetabolism. Nat Metab. 2023; 5(7):1101-1110. DOI: 10.1038/s42255-023-00843-6. View

20.

Arioglu E, Andewelt A, Diabo C, Bell M, Taylor S, Gorden P . Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002; 81(2):87-100. DOI: 10.1097/00005792-200203000-00001. View